

## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/682,667	10/04/2001	Aaron J.W. Hsueh	STAN072CON

24353  
BOZICEVIC, FIELD & FRANCIS LLP  
200 MIDDLEFIELD RD  
SUITE 200  
MENLO PARK, CA 94025

**RECEIVED**  
DEC 28 2001  
TECH CENTER 1600/2900

CONFIRMATION NO. 8958

## FORMALITIES LETTER



\*OC000000006961791\*

Date Mailed: 10/24/2001

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



RECEIVED  
DEC 28 2001  
TECH CENTER 1600/2900

#4

**NOTIFICATION OF PRIOR SEQUENCE LISTING**

Application Number	09/682,667
Confirmation Number	8958
Filing Date	October 4, 2001
First Named Inventor	Hsueh et al.
Examiner	Not yet assigned
Group Art	1642
Attorney Docket No.	STAN072CON

ADDRESS TO: Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The above-identified patent application contains sequences of nucleic acid and polypeptides. A sequence listing was prepared for parent application, Serial No. 09/517,358, filed March 2, 2000, in paper and computer-readable format. The sequences in the present application are identical to those presented in the parent application. Therefore, please transfer to this application, in accordance with 37 CFR 1.821(e), the computer readable copy from applicants' other application.

Applicants respectfully submit that the present patent application is now in compliance with 37 CFR 1.821 - 1.825.

The Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account 50-0815 order No. STAN072CON. If additional fees are required, including extensions of time, please consider this a petition therefore.

**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED**

Name (Print/Type)	Pamela J. Sherwood		Registration No.	36,677	
Signature				Date	12-21-2001
Firm Name	Bozicevic, Field & Francis LLP		Address	200 Middlefield Road, Suite 200	
City	Menlo Park	State	California	zip	94025
Telephone - Direct Dial	650-833-7790		Facsimile	650-327-3231	

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231.

Name (Print/Type)	Susan M. Alessi	Signature		Date	12/21/01
-------------------	-----------------	-----------	--	------	----------

#4

# AMINO ACID AND NUCLEOTIDE SEQUENCE LISTING FOR A PATENT APPLICATION

Electronic Version 1.0.1

Stylesheet Version 1.0.1

## STATEMENT REGARDING SEQUENCE(S)

This is a request for filing the electronic copy of a sequence listing for a patent application under 37 C.F.R. 1.821-1.825.

This communication has an attached file which is the electronic copy of the amino acid and/or nucleotide sequence listing for the previously mentioned United States Patent Application.

The electronic copy submitted herewith is the Computer Readable Form (CRF), as required by 1.821(e).

Any applicable fees associated with the filing of the electronic copy have been paid.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter). It may be in addition to an original CRF, filed to comply with the sequence rules.

This submission in electronic form comprises only the CRF of 37 C.F.R. 1.821(e). Applicant is responsible for all additional requirements of amino acid and/or nucleotide sequence listing submissions as specified in 37 C.F.R. 1.821 - 1.825.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter), and/or is in addition to an original CRF filed to comply with the sequence rules. If not made to comply with an originally filed CRF, it is identical to the sequences disclosed in the application as originally filed and/or the paper copy of the Sequence Listing as originally filed.

### Attachment Description:

MS-WINDOWS FAST SEQ ver. 4.0 ASCII-DOS TEXT Format 09/682,667 FILED OCT.  
4, 2001 HSUEH et al. STAN072CON

**COPY**

Acknowledgment Receipt:

APPLICATION NUMBER: 09682667

FIRST NAMED INVENTOR: AARON HSUEH

TITLE OF INVENTION: MAMMALIAN PRO-APOPTOTIC BOK GENES AND THEIR USES

ATTORNEY DOCKET NUMBER: STAN072CON

FILE LISTING:

transequence.xml 6508 Bytes

sequencebio.xml 1043 Bytes

u-bio.dtd 3619 Bytes

e-bioseq.xsl 6067 Bytes

SEQLIST.TXT 16842 Bytes

EFS ID: 12558

FILE SIZE: 18795 Bytes

TIMESTAMP: Fri Oct 05 12:46:21 EDT 2001

MESSAGE DIGEST: ykqdDZx+zl51x+baVtSq5w==

DIGITAL CERTIFICATE HOLDER NAME: cn=Pamela J. Sherwood, ou=Registered Attorneys

UPLOAD STATUS: You have successfully uploaded your submission to USPTO

DOCKETED  
*Electronic filing*  
10/5/01